Analyst Price Targets — PCSA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 19, 2022 9:10 am | — | Maxim Group | $225.00 | $79.61 | Benzinga | Maxim Group Initiates Coverage On Processa Pharma with Buy Rating, Announces Price Target of $9 |
Latest News for PCSA
Heatwurx (NASDAQ: PCSA - Get Free Report) and Stevanato Group (NYSE: STVN - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Analyst Recommendations This is a breakdown of recent ratings
Heatwurx (NASDAQ: PCSA - Get Free Report) and Aquestive Therapeutics (NASDAQ: AQST - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Profitability This table compares Heatwurx and Aquestive Therapeutics'
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCSA.
U.S. House Trading
No House trades found for PCSA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.